BMS - Rumblings about restructuring in R&D?

Hey everyone, been hearing some whispers lately about potential shifts within the R&D side of BMS. Nothing concrete, no official announcements or anything, but there's a definite buzz. Some teams seem to be undergoing 'process reviews' which feels like a classic prelude. I'm in [mention a general area, e.g., early discovery/clinical development] and while my immediate team hasn't seen anything direct, the overall atmosphere feels a bit tense. Is anyone else in R&D picking up on this? Wondering if it's just general industry slowdown impacting us or something more specific to BMS. Trying not to panic, but the uncertainty is a bit much. Anyone have insights or heard similar things?